Abstract 670P
Background
Tinengotinib is a spectrum-selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, and immune-oncology pathways by inhibiting Aurora kinases A/B, Janus kinases and receptor tyrosine kinases (FGFRs and VEGFRs). Tinengotinib has shown promising clinical signal in solid tumors from several studies globally. Here we present the interim data from a phase Ib/II trial in China.
Methods
Pts with advanced/metastatic solid tumors were enrolled and treated with tinengotinib in 21-day cycle. Monotherapy and combination therapy with dose escalation (phase Ib) and dose expansion (phase II) were designed.
Results
As of 5-Mar-2023, thirty-three (33) pts have received tinengotinib monotherapy. Median age was 58.0 years (29-81), 66.7% were male, 81.8% had ECOG of 1, 87.9% had stage IV disease, 69.7% had ≥3 lines of prior therapies. No DLT was observed in phase Ib (3 pts in each group of 8, 10, 12 mg QD). 10 mg QD was selected as RP2D. Treatment-related AEs (TRAEs) were reported in 30 (90.9%) pts, Gr 3 in 14 (42.4%), Gr 4 in 1 (3.0%), and no Gr 5. The most common TRAEs (≥30%) included abnormal laboratory parameters (blood thyroid stimulating hormone increased, white blood cell count decreased, neutrophil count decreased, aspartate aminotransferase increased, alanine aminotransferase increased), palmar-plantar erythrodysaesthesia syndrome and anaemia. Among 22 efficacy-evaluable pts, the median Progression-free survival (PFS) have reached 6.70 (95% CI, 3.22-NA) months. For 19 pts with measurable target lesions, the overall response rate (ORR) and disease control rate (DCR) were 15.8% and 89.5%, respectively. For 4 CCA pts harboring FGFR2 alteration, ORR was 50%, DCR was 100%. One responder with prior treatment of erdafitinib achieved tumor reduction of 44%, the other with no prior FGFR inhibitor treatment achieved 69% reduction.
Conclusions
Tinengotinib monotherapy was well-tolerated in Chinese pts and 10 mg QD was selected as RP2D. Promising efficacy has been observed, especially in CCA with FGFR2 alteration. The ongoing study is to further evaluate the safety and efficacy of monotherapy and combination therapy.
Clinical trial identification
NCT05253053.
Editorial acknowledgement
Legal entity responsible for the study
TransThera Sciences (Nanjing), Inc.
Funding
TransThera Sciences (Nanjing), Inc.
Disclosure
J. Fan: Financial Interests, Personal, Officer, I am Chief Medical Officer, full time employee at TransThera Sciences, Inc.: TransThera Sciences, Inc.; Financial Interests, Personal, Stocks/Shares, I owned AstraZeneca's stocks: AstraZeneca; Non-Financial Interests, Member: ASCO, ESMO, AACR. L. Shen: Financial Interests, Personal, Other, Consulting fees: Mingji biopharmaceutical, Haichuang pharmaceutical, Herbour biomed; Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, BI, Sanofi, Roche, Servier, AZ; Financial Interests, Institutional, Funding: Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Alphamab Oncology, Yaojie Ankang (Nanjing) Technology Co., Ltd., BeiGene, Ltd., Qiyu Biotechnology (Shanghai) Co., Ltd., BriSTAR Immunotech; Financial Interests, Institutional, Local PI: Merck Healthcare KGaA, Roche; Financial Interests, Institutional, Trial Chair: Rongchang Pharmaceutical, Innovent, BeiGene, Ltd., Qilu Pharmaceutical, NovaRock Biotherapeutics Limited. All other authors have declared no conflicts of interest.
Resources from the same session
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17
117P - Genomic landscape of biliary tract cancers from India show distinct geographic variation
Presenter: Nitesh Rohatgi
Session: Poster session 17
118P - Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Presenter: Yeonghak Bang
Session: Poster session 17
119P - Management of biliary tract cancers in older patients: A French multicenter cohort study
Presenter: Marine Valery
Session: Poster session 17
120P - Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Presenter: Antoine Lebeaud
Session: Poster session 17
121P - PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Presenter: Blandine Delaunay
Session: Poster session 17
122P - Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Presenter: Umair Mahmood
Session: Poster session 17
123P - Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Presenter: Gwangil Kim
Session: Poster session 17
124P - Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Maria Bensi
Session: Poster session 17
125P - Real-world treatment patterns in patients with biliary tract cancer (BTC): Retrospective chart review survey in Europe (GARNET-2)
Presenter: John Bridgewater
Session: Poster session 17